In a Nature Review publication, Linda Koch suggested the inhibition of RANKL as a probable new anticancer strategy [14], and this has been re-echoed even more recently, as the inhibition of RANKL/RANK signaling, which regulates progesterone-mediated development of the lactating mammary gland, breast stem cell proliferation and expansion, and drives the formation of hormone-induced breast cancer, is again flaunted as a likely effective anticancer therapeutic option [15]. Here, TNFSF11 is linked to breast carcinoma.